Randomized Trial of the Efficacy and Safety of Berotralstat (BCX7353) as an Oral Prophylactic Therapy for Hereditary Angioedema: Results of APeX-2 Through 48 Weeks (Part 2).

MLA

Wedner, H.James, et al. “Randomized Trial of the Efficacy and Safety of Berotralstat (BCX7353) as an Oral Prophylactic Therapy for Hereditary Angioedema: Results of APeX-2 Through 48 Weeks (Part 2).” The Journal of Allergy and Clinical Immunology. In Practice, vol. 9, no. 6, June 2021, p. 2305. EBSCOhost, https://doi.org/10.1016/j.jaip.2021.03.057.

APA

Wedner, H. J., Aygören-Pürsün, E., Bernstein, J., Craig, T., Gower, R., Jacobs, J. S., Johnston, D. T., Lumry, W. R., Zuraw, B. L., Best, J. M., Iocca, H. A., Murray, S. C., Desai, B., Nagy, E., Sheridan, W. P., & Kiani-Alikhan, S. (2021). Randomized Trial of the Efficacy and Safety of Berotralstat (BCX7353) as an Oral Prophylactic Therapy for Hereditary Angioedema: Results of APeX-2 Through 48 Weeks (Part 2). The Journal of Allergy and Clinical Immunology. In Practice, 9(6), 2305. https://doi.org/10.1016/j.jaip.2021.03.057

Chicago

Wedner, H James, Emel Aygören-Pürsün, Jonathan Bernstein, Timothy Craig, Richard Gower, Joshua S Jacobs, Douglas T Johnston, et al. 2021. “Randomized Trial of the Efficacy and Safety of Berotralstat (BCX7353) as an Oral Prophylactic Therapy for Hereditary Angioedema: Results of APeX-2 Through 48 Weeks (Part 2).” The Journal of Allergy and Clinical Immunology. In Practice 9 (6): 2305. doi:10.1016/j.jaip.2021.03.057.